Top Markets
#1 Islamic Coin Islamic Coin +154.49%
#2 PulseChain PulseChain +49.22%
#3 RedStone RedStone +25.04%
#4 Nockchain Nockchain +12.19%
#5 Not in Employment, Education, or Training Not in Employment, Education, or Training +11.86%
#6 MarsCoin MarsCoin +10.80%
#7 SkyAI SkyAI +9.90%
#8 BOOK OF MEME BOOK OF MEME +9.54%
#9 Monad Monad +9.18%
#10 Ergo Ergo +8.50%
Coin of the day
Islamic Coin Islamic Coin
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Angion Biomedica Corp. Angion Biomedica Corp.

Angion Biomedica Corp.

ANGN
Rang in aandelen #27863
Angion Biomedica Corp. operates as a biopharmaceutical enterprise,... Angion Biomedica Corp. operates as a biopharmaceutical enterprise, concentrating its efforts on the identification, advancement, and market introduction of small molecule treatments for severe organ damage and scarring conditions. Its primary investigational compound, ANG-3070, is an orally administered tyrosine kinase receptor inhibitor currently being developed to address fibrotic ailments, particularly those impacting the kidneys and lungs. The company's product pipeline also features ANG-3777, a hepatocyte growth factor mimetic engineered to treat acute organ injuries like delayed graft function, in addition to initiatives for ROCK2 inhibitors targeting fibrotic diseases and a CYP11B2 inhibitor program. Established in 1998, Angion Biomedica Corp. maintains its headquarters in Uniondale, New York.
Aandeelprijs
$1.00
Laatst gesynchroniseerd: 2023-06-01
Marktkapitalisatie
$30.11M
Verandering (1 dag)
2.04%
Verandering (1 jaar)
0.00%
Land
US
Handel Angion Biomedica Corp. (ANGN)

Categorie

Healthcare
Winst voor Angion Biomedica Corp. (ANGN)
Winst in 2026 TTM: 0
Volgens de meest recente financiële verslagen van Angion Biomedica Corp. bedraagt de huidige winst van het bedrijf 0. In 2026 behaalde het bedrijf een winst van 0, gelijk aan de winst van 2026, die 0 bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Angion Biomedica Corp. van 2026 tot 2026
Winst aan het einde van elk jaar
Jaar Winst Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Winst van vergelijkbare bedrijven of concurrenten
Bedrijf Winst Winstverschil Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH